Publication | Closed Access

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

First-line TherapyOncologyPathologyEgfr MutationsCancer TreatmentCancer GeneticsPhase 2MedicineRadiation OncologyLung CancerMolecular Oncology